ABIVAX Société Anonyme

NasdaqGM:ABVX Stock Report

Market Cap: US$10.7b

ABIVAX Société Anonyme Management

Management criteria checks 3/4

ABIVAX Société Anonyme's CEO is Marc M. de Garidel, appointed in May 2023, has a tenure of 3.17 years. total yearly compensation is €1.15M, comprised of 52.3% salary and 47.7% bonuses, including company stock and options. directly owns 0.58% of the company’s shares, worth $61.98M. The average tenure of the management team and the board of directors is 3.1 years and 5 years respectively.

Key information

Marc M. de Garidel

Chief executive officer

€1.1m

Total compensation

CEO salary percentage52.30%
CEO tenure3.2yrs
CEO ownership0.6%
Management average tenure3.1yrs
Board average tenure5yrs

Recent management updates

Recent updates

Seeking Alpha • Jun 30

Abivax: Latest Obefazimod Data Eases Safety Fears, Brings M&A Back Into Play

Summary ABIVAX Société Anonyme surged >35% on positive Phase 3 data for obefazimod in ulcerative colitis, reinforcing its differentiated, multi-pathway mechanism and best-in-class profile. Recent safety data alleviated cancer concerns, with malignancy rates consistent with UC background and no expected boxed warning, supporting a clear regulatory path. Obefazimod’s efficacy and oral administration position ABVX as a serious competitor to established immunology drugs, with potential $4bn annual sales in a ~$30bn market. I see at least 30% further upside if obefazimod secures U.S. approval, with M&A speculation offering >120% potential based on rumored acquisition prices. Read the full article on Seeking Alpha
Seeking Alpha • Mar 27

ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts

Summary ABIVAX is a French company that IPO-ed in the US in 2023 and is running a phase 3 trial for ulcerative colitis. Their lead candidate, obefazimod, is in phase 3 trials for moderate to severe ulcerative colitis and has a novel mechanism of action. The company faces competition from other approved treatments for ulcerative colitis, but their drug has shown promising efficacy and a good safety profile. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Marc M. de Garidel's remuneration changed compared to ABIVAX Société Anonyme's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-€332m

Dec 31 2025€1m€601k

-€336m

Sep 30 2025n/an/a

-€294m

Jun 30 2025n/an/a

-€195m

Mar 31 2025n/an/a

-€186m

Dec 31 2024€631k€578k

-€176m

Sep 30 2024n/an/a

-€185m

Jun 30 2024n/an/a

-€177m

Mar 31 2024n/an/a

-€165m

Dec 31 2023€794k€359k

-€148m

Compensation vs Market: Marc M.'s total compensation ($USD1.31M) is below average for companies of similar size in the US market ($USD14.47M).

Compensation vs Earnings: Marc M.'s compensation has increased whilst the company is unprofitable.

CEO

Marc M. de Garidel (68 yo)

3.2yrs
Tenure
€1,148,314
Compensation

Mr. Marc M. P. de Garidel, M.B.A., serves as Director of Claris Biotherapeutics, Inc. He has been CEO at ABIVAX Société Anonyme since May 5, 2023 and serves as its Director. He had been Interim Chair of th...

Leadership Team

NamePositionTenureCompensationOwnership
Marc M. de Garidel
CEO & Director3.2yrs€1.15m0.58%
$ 62.0m
Didier Blondel
EVP, CFO & Board Secretary9.5yrsno data0.00047%
$ 50.1k
Patrick Malloy
Senior VP & Head of Investor Relations2.9yrsno datano data
Ida Hatoum
Chief People & Compliance Officer3.1yrsno datano data
Pierre Courteille
Chief Business Officerno datano data0%
$ 0
Jerome Denis
Executive Vice President of Process Development & Manufacturing2.8yrsno datano data
Hema Keshava
Senior Vice President of Financeno datano datano data
Chris Rabbat
VP & Global Head of Medical Affairsno datano datano data
Kevin Shan
VP & Global Head of Biometricsno datano datano data
Mary Mantock
Senior VP & Global Head of Regulatory Affairsno datano datano data
Douglas Jacobstein
Senior VP & Global Head of Clinical Developmentno datano datano data
Nadege Briancon-Eris
Global Head of Development Operations & SVPno datano datano data
3.1yrs
Average Tenure
59.5yo
Average Age

Experienced Management: ABVX's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marc M. de Garidel
CEO & Director3.2yrs€1.15m0.58%
$ 62.0m
Sylvie Gregoire
Independent Chair of the Board2yrs€143.75kno data
Christian Brechot
Member of Scientific Advisory Board8.8yrsno datano data
Christian Trepo
Member of Scientific Advisory Boardno datano datano data
Lawrence Stanberry
Member of Scientific Advisory Boardno datano datano data
Troy Ignelzi
Independent Director3yrs€128.75k0%
$ 0
Christoph Huber
Member of Scientific Advisory Boardno datano datano data
Claude Bertrand
Member of Scientific Advisory Board6.8yrs€4.94kno data
Luc Teyton
Member of Scientific Advisory Boardno datano datano data
June H. Lee
Independent Director3yrs€127.50k0%
$ 0
Corinna Bonsen-Thomas
Independent Non-Executive Director9.1yrs€115.00k0%
$ 0
Ian McGowan
Chairman of Scientific Advisory Board8.1yrsno datano data
5.0yrs
Average Tenure
65.5yo
Average Age

Experienced Board: ABVX's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/01 10:51
End of Day Share Price 2026/07/01 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ABIVAX Société Anonyme is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Julian HarrisonBTIG
Jason ButlerCitizens JMP Securities, LLC